1. Search Result
Search Result
Results for "

molecular modelling

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

3

Screening Libraries

2

Fluorescent Dye

1

Biochemical Assay Reagents

4

Peptides

2

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1571

    NP 396

    Arenavirus Inflammation/Immunology
    Nucleoprotein (396-404) is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .
    Nucleoprotein (396-404)
  • HY-P1571A

    NP 396 TFA

    Arenavirus Inflammation/Immunology
    Nucleoprotein (396-404) TFA is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) TFA is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .
    Nucleoprotein (396-404) (TFA)
  • HY-157214

    STING Molecular Glues Cancer
    NVS-STG2 is a molecular glue that targets STINGmolecular glue. NVS-STGI enhances the activity of cGAMP by inducing the formation of more abundant and larger oligomers. NVS-STG2 produces antitumor activity in animal models .
    NVS-STG2
  • HY-126359

    SLPC; 18:0-18:2 PC

    Endogenous Metabolite Metabolic Disease
    1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can be chosen as a model used to investigate the volatile compounds from oxidised phosphatidylcholine molecular species. This method is applied to a real food sample, i.e. soy lecithin .
    1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine
  • HY-116282C

    DSS (MW 35000-45000); DXS (MW 35000-45000)

    Apoptosis Infection Inflammation/Immunology
    Dextran sulfate sodium salt (DSS) (MW 35000-45000) is a polymer of dehydrated glucose with a molecular weight of approximately 35000-45000. DSS with different molecular weights exhibits different biological activities. Dextran sulfate sodium salt (DSS) (MW 35000-45000) is a potent inducer of colitis. Dextran sulfate sodium salt (DSS) (MW 35000-45000) can be used to induce model acute colitis, chronic colitis, and colitis-related colon cancer. Dextran sulfate sodium salt (DSS) (MW 35000-45000) may be related to macrophage dysfunction, intestinal flora dysbiosis, and is particularly toxic to the colonic epithelium .
    Dextran sulfate sodium salt (MW 35000-45000)
  • HY-176347S

    Isotope-Labeled Compounds Cancer
    Alpha Feto Protein, Arg- 13C36, 15N4, Lys- 13C6, 15N2 is the 13C- and 15N-labeled Alpha Feto Protein.
    Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2
  • HY-149646

    HDAC Cancer
    HDAC6-IN-24 (compound N1) is a inhibitor of HDAC6 .
    HDAC6-IN-24
  • HY-156754

    Cholinesterase (ChE) Neurological Disease
    3β-Hydroxy-lup-20(29)-en-16-one (compound 9) is a dual inhibitor of AChE and BChE, with selectivity for BChE (IC50: 28.9 μM) .
    3β-Hydroxy-lup-20(29)-en-16-one
  • HY-137612

    Uridine 5'-O-1-thiotriphosphate

    P2Y Receptor Cancer
    Sp-UTP-α-S is a P2Y2 and P2Y4 receptor activator. Sp-UTP-α-S can be used in cancer research .
    Sp-UTP-α-S
  • HY-P2138

    HIV Protease Others
    U-85548E is an HIV protease inhibitor with nanomolar affinity for HIV-1 aspartic protease. By studying its structure-activity relationship, a potent nanomolar inhibitor with inhibitory effects on both HIV-1 and HIV-2 proteases was designed, and its binding mode was studied by X-ray crystallography and molecular modeling.
    U-85548E
  • HY-168625

    Molecular Glues Inflammation/Immunology
    VAV1 degrader-3 (Example 185) is an orally active VAV1 molecular glue degrader (DC50: 7 nM). VAV1 degrader-3 reduces immune cell activation, immune cell proliferation and the production of various cytokines. VAV1 degrader-3 can be used for research of inflammatory or autoimmune disorder. VAV1 degrader-3 inhibits disease progression in experimntal autoimmune encephalomyelitis (EAE) mouse model, Collagen-induced arthritis (CIA) mouse model, etc. .
    VAV1 degrader-3
  • HY-169347

    LC-05-004

    Molecular Glues Casein Kinase Cancer
    dCK1α-2 is an orally active CK1α molecular glue degrader that targets p53 pathway-related targets. dCK1α-2 exhibits anti-tumor efficacy in mouse models and can increase the expression of p53-related genes. .
    dCK1α-2
  • HY-N10487

    Cholinesterase (ChE) Neurological Disease
    Bleformin A is a potent BChE inhibitor with an IC50 value of 5.2 μM. Bleformin A is a nature product that could be isolated from Bletilla striata. Bleformin A can be used for research of Alzheimer's disease (AD) .
    Bleformin A
  • HY-W181530

    Molecular Glues CDK Apoptosis Ligands for E3 Ligase Cancer
    NCT02 is a molecular glue degrader based on the E3 ubiquitin ligase DDB1 that targets CDK12 and its binding partner CCNK. NCT02 triggers the ubiquitination and proteasomal degradation of CCNK, thereby downregulating CDK12 protein levels and inhibiting its downstream signaling pathways. NCT02 can induce tumor cell apoptosis, arrest the cell cycle, and selectively inhibit the proliferation of colorectal cancer cells carrying TP53 defects or belonging to the consensus molecular subtype CMS4. NCT02 has the potential to inhibit tumor growth in in vitro and in vivo models .
    NCT02
  • HY-161767

    Molecular Glues Cancer
    JWJ-01-306 is a molecular glue that targets the C2H2 zinc finger transcription factor ZBTB11. JWJ-01-306 degrades ZBTB11, reduces the oxidative phosphorylation (OXPHOS) and tricarboxylic acid (TCA) cycle, and inhibits the proliferation of KAS-resistant PDAC cells. JWJ-01-306 exhibits good pharmacokinetic characteristics in mouse model .
    JWJ-01-306
  • HY-161779

    Molecular Glues Epigenetic Reader Domain Apoptosis Cancer
    PLX-3618 is a molecular glue, that degrades BRD4 with DC50 of 12.2 nM. PLX-3618 promotes polyubiquitination and subsequent proteasomal degradation of BRD4 by recruiting of the E3 ligase substrate receptor, DCAF11. PLX-3618 inhibits the proliferation of various cancer cells, induces apoptosis in AML cells. PLX-3618 exhibits antitumor activity against AML in mouse models .
    PLX-3618
  • HY-13072
    Cenisertib
    1 Publications Verification

    AS-703569; R-763

    Aurora Kinase Bcr-Abl Akt STAT FLT3 Cancer
    Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .
    Cenisertib
  • HY-13072B

    AS-703569 benzoate; R-763 benzoate

    Aurora Kinase Bcr-Abl Akt STAT FLT3 Cancer
    Cenisertib (AS-703569) benzoate is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib benzoate induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib benzoate inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .
    Cenisertib benzoate
  • HY-117093

    HDAC Cancer
    H8-A5 is a novel human histone deacetylase 8 (HDAC8) inhibitor. A highly specific ZBG-based pharmacophore model was developed by incorporating a custom zinc-binding group (ZBG) feature. Pharmacophore-based virtual screening identified three novel HDAC8 inhibitors with low micromolar IC50 values (1.8-1.9 μM). Further studies showed that H8-A5 was more selective for HDAC8 than HDAC1/4 and exhibited antiproliferative activity in MDA-MB-231 cancer cells. Molecular docking and molecular dynamics studies showed that H8-A5 could bind to HDAC8, providing a good starting point for the development of HDAC8 inhibitors for cancer treatment.
    H8-A5
  • HY-13072R

    Aurora Kinase Bcr-Abl Akt STAT FLT3 Cancer
    Cenisertib (Standard) is the analytical standard of Cenisertib. This product is intended for research and analytical applications. Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .
    Cenisertib (Standard)
  • HY-103609
    Pyrene
    1 Publications Verification

    Benzo[def]phenanthrene

    Biochemical Assay Reagents Others
    Pyrene is a polycyclic aromatic hydrocarbon (PAH) composed of four fused benzene rings. It has a distinct aromatic odor, produced by incomplete combustion of organic matter. Pyrene exhibits strong fluorescence, emitting in the blue region of the spectrum, making it useful as a probe for studying molecular interactions in solution and on surfaces. Pyrene is also used as a model compound for the study of PAHs in various environments and biological systems because of its ubiquity in these environments. However, long-term exposure to pyrene has been associated with potential health risks, including carcinogenicity and mutagenicity.
    Pyrene
  • HY-124388

    Phosphodiesterase (PDE) Inflammation/Immunology
    PDE4-IN-20 is a selective submicromolar phosphodiesterase-4 (PDE4) inhibitor with anti-TNF-α properties. PDE4-IN-20 exhibits significant biological activity in vitro and in vivo. The mechanism of action of PDE4-IN-20 is supported by molecular modeling studies, which reveal its binding mode with PDE4. PDE4-IN-20 was optimized in further conformational analysis and showed pharmacological characteristics similar to those of known PDE4 inhibitors .
    PDE4-IN-20
  • HY-155760

    VEGFR Carbonic Anhydrase Cancer
    hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-3 inhibits VEGFR-2 (IC50=358 nM), has high binding activity to hCAs with Ki of 4.2 nM (hCA IX), 22.9 nM (hCA II), 25.1 nM (hCA I), 28.0 nM (hCA XII), respectively. hCA/VEGFR-2-IN-3 has antiproliferative activity against VEGFR-2 overexpressing breast cancer cells .
    hCA/VEGFR-2-IN-3
  • HY-155763

    VEGFR Carbonic Anhydrase Cancer
    hCA/VEGFR-2-IN-4 (compound 15b) is an indolinylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-4 inhibits VEGFR-2 (IC50=0.811 μM) and has high binding activity to hCAs, with Ki of 3.8 nM (hCA XII), 6.2 nM (hCA IX), 19.8 nM (hCA II), and 35.5 nM (hCA I), respectively. hCA/VEGFR-2-IN-4 has antiproliferative activity on VEGFR-2-overexpressing breast cancer cells .
    hCA/VEGFR-2-IN-4
  • HY-155758

    VEGFR Carbonic Anhydrase Cancer
    hCA/VEGFR-2-IN-2 (compound 8g) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-2 inhibits VEGFR-2 (IC50=204 nM) and has high binding activity to hCAs, with Kis of 3.6 nM (hCA IX), 16.1 nM (hCA II), 16.7 nM (hCA XII), and 75.3 nM (hCA I), respectively. hCA/VEGFR-2-IN-2 has antiproliferative activity on VEGFR-2-overexpressing breast cancer cells .
    hCA/VEGFR-2-IN-2
  • HY-108610A

    ET-18-OCH3

    Apoptosis Cancer
    Edelfosine (ET-18-OCH3) is a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 Death receptor .
    Edelfosine
  • HY-173116

    Carbonic Anhydrase Cancer
    DOTA-XYIMSR-01 is a molecular probe targeting CAIX that can be labeled with 177Lu for the inhibition and localization of malignant gliomas. The uptake of [177Lu] Lu-XYIMSR-01 in U87MG tumors is 6.19 % of the injected dose per gram (% ID/g), and the tumor-to-muscle uptake ratio is 20.14. In the orthotopic glioma model, combined injection with Temozolomide (HY-17364) can significantly improve the survival rate of mice and inhibit tumor growth. DOTA-XYIMSR-01 shows promise for research in the field of anti-cancer therapy .
    DOTA-XYIMSR-01
  • HY-103609R

    Benzo[def]phenanthrene (Standard)

    Biochemical Assay Reagents Reference Standards Others
    Pyrene (Standard) is the analytical standard of Pyrene. This product is intended for research and analytical applications. Pyrene is a polycyclic aromatic hydrocarbon (PAH) composed of four fused benzene rings. It has a distinct aromatic odor, produced by incomplete combustion of organic matter. Pyrene exhibits strong fluorescence, emitting in the blue region of the spectrum, making it useful as a probe for studying molecular interactions in solution and on surfaces. Pyrene is also used as a model compound for the study of PAHs in various environments and biological systems because of its ubiquity in these environments. However, long-term exposure to pyrene has been associated with potential health risks, including carcinogenicity and mutagenicity.
    Pyrene (Standard)
  • HY-170574

    Molecular Glues Ser/Thr Kinase Apoptosis Cancer
    CQ627 is a molecular glue targeting the degradation of RIOK2. It effectively induces the degradation of RIOK2 in the MOLT4 leukemia cell line via the ubiquitin-proteasome system (UPS) by recruiting the E3 ubiquitin ligase RNF126, with a DC50 value of 410 nM. CQ627 dose-dependently induces apoptosis in MOLT4 leukemia cells, blocks their cell cycle in the G2/M phase, and exhibits antiproliferative activities in various cancer cell lines. CQ627 also demonstrates in vivo anticancer activity in a MOLT4 xenograft mouse model .
    CQ627
  • HY-172533

    STING Cancer
    3’,5’-DiOA-dC is a hydrophobic nucleotide lipid and a ligand for the STING agonist c-di-GMP (CDG). 3’,5’-DiOA-dC can assemble with CDG and form stable cyclic dinucleotide nanoparticles via various supramolecular forces driven by molecular recognition. 3’,5’-DiOA-dC can decrease tumor weight and volume, increase CD8 T cell, neutrophils as well as NK cell counts in tumor microenvironment in combination with CDG. 3’,5’-DiOA-dC also increases the levels of TNF-α and IFN-γ in murine melanoma model .
    3′,5′-DiOA-dC
  • HY-123960
    Raphin1
    3 Publications Verification

    Phosphatase Neurological Disease
    Raphin1 is an orally bioavailable, selective inhibitor of the regulatory phosphatase PPP1R15B (R15B). Raphin1 binds strongly to the R15B-PP1c holophosphatase (Kd=33 nM), and shows ~30-fold selective in binding R15B-PP1c over R15A-PP1c. Raphin1 crosses the blood-brain barrier, and reduces organismal and molecular deficits in a mouse model of a protein misfolding disease .
    Raphin1
  • HY-149127

    ASC-JM17; ALZ-003

    Keap1-Nrf2 Androgen Receptor HSP Mitophagy Metabolic Disease
    Rosolutamide (ASC-JM17), a curcumin analog, is an orally active, potent Nrf1 and Nrf2 activator. Rosolutamide activates Nrf1, Nrf2 and heat shock factor 1 (Hsf1), thereby activating the expression of proteasome subunits, antioxidant enzymes and molecular chaperones. Rosolutamide degrades the polyglutamine (polyQ) androgen receptor (AR) via the ubiquitin-proteasome pathway and improves motor function in mouse models of spinal and bulbar muscular atrophy (SBMA). Rosolutamide improves mitochondrial function and promotes autophagy, decreases mutant protein aggregates, and attenuates intracellular/mitochondrial reactive oxygen species (ROS) levels .
    Rosolutamide
  • HY-123960A
    Raphin1 acetate
    3 Publications Verification

    Phosphatase Neurological Disease
    Raphin1 acetate is an orally bioavailable, selective inhibitor of the regulatory phosphatase PPP1R15B (R15B). Raphin1 acetate binds strongly to the R15B-PP1c holophosphatase (Kd=33 nM), and shows ~30-fold selective in binding R15B-PP1c over R15A-PP1c. Raphin1 acetate crosses the blood-brain barrier, and reduces organismal and molecular deficits in a mouse model of a protein misfolding disease .
    Raphin1 acetate
  • HY-15007

    Oxytocin Receptor Endocrinology
    L 366509 is a spiroindenylpiperidine camphorsulfonamide oxytocin (OT) antagonist. Modifications led to a new series of o-tolylpiperazine (TP) camphorsulfonamides, exhibiting high affinity for OT receptors and selectivity over arginine vasopressin receptors. Notably, compound 7 (L-368,899) showed excellent OT receptor affinity, potency in inhibiting OT-stimulated uterine contractions, good aqueous solubility, and oral bioavailability in multiple species. Compound 7 has entered clinical testing as an oral and intravenous tocolytic agent. Molecular modeling suggests the TP camphorsulfonamide structure mimics the D-AA2-Ile3 dipeptide, crucial in potent OT antagonists .
    L 366509
  • HY-172930

    Molecular Glues IKZF Family Potassium Channel Inflammation/Immunology Cancer
    PVTX-405 is a selective and oral active IKZF2 molecular glue degrader with a DC50  of  0.7 nM and a Dmax of 91%. PVTX-405 enhances degradation efficiency, significantly reduces off-target degradation, and alleviates hERG inhibition with IC50 of 48 µM. PVTX-405 significantly inhibits the growth of MC38 tumors, with greater synergistic anti-cancer efficacy in combination with immune checkpoint therapies (ICTs) (anti-PD1 or anti-LAG3) in the MC38 mouse tumor xenograft model using Crbn 391V C57BL/6 mice .
    PVTX-405
  • HY-163691

    Carbonic Anhydrase Cancer
    Antitumor agent-163 (Compound 3) is a photosensitizer used in Molecular-Targeted Photodynamic Therapy (MT-PDT) targeting carbonic anhydrase IX (CAIX). Antitumor agent-163 inactivates CAIX protein via singlet oxygen under 540 nm wavelength light, without affecting internal standard proteins such as α-tubulin, β-actin, and proliferating cell nuclear antigen (PCNA). Antitumor agent-163 induces cell membrane damage, inhibits cell viability (IC50 is 0.2 and 0.05 μM for A549 and U87MG). Antitumor agent-163 exhibits antitumor efficacy in mouse model .
    Antitumor agent-163
  • HY-126969

    PPAR Metabolic Disease
    C333H is a selective PPARγ modulator with insulin-sensitizing and hypoglycemic activities. C333H exhibits similar insulin-sensitizing effects to thiazolidinediones (TZDs) in diabetic mouse models without significantly increasing body weight or adipose tissue weight. C333H increases circulating high molecular weight adiponectin isoform levels in diabetic db/db mice, reduces serine phosphorylation of PPARγ 273 in brown adipose tissue, and selectively modulates the expression of specific PPARγ target genes in adipose tissue. Express. C333H exhibits weak recruitment of co-activators and weak dissociation of co-repressors in vitro. These properties suggest that C333H may be a potential inhibitor of type 2 diabetes .
    C333H
  • HY-P10792

    EGFR Cancer
    HER2-targeted peptide H6F is a HER2 targeting peptide that binds to HER2 to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .
    HER2-targeted peptide H6F
  • HY-149009

    Bcl-2 Family Apoptosis Cancer
    Bcl-2-IN-9 is a novel proapoptotic Bcl-2 inhibitor with IC50 value of 2.9 μM and low cytotoxic. Bcl-2-IN-9 mediates apoptosis by down-regulating expression of Bcl-2 in cancer cells and has a high selectivity against leukemia cells .
    Bcl-2-IN-9
  • HY-160777

    Galeterone 3β-imidazole

    Molecular Glues Androgen Receptor MNK Apoptosis Cancer
    VNPP433-3β (Galeterone 3β-imidazole) is an orally active molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2.VNPP433-3β induces cell apoptosis. VNPP433-3β inhibits proliferation of cancer cell LNCaP, C4-2B and CWR22Rv1 with GI50 of 0.2, 0.3 and 0.31 μM. VNPP433-3β exhibits good pharmacokinetic characters in CD-1 mouse and inhibits tumor growth in the CWR22Rv1 xenograft mouse model. VNPP433-3β can be used for the study of castration resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC) .
    VNPP433-3β
  • HY-112624H

    Dextran 2; Dextran D2; Dextran T2(MW 1600-2400)

    Biochemical Assay Reagents Others
    Dextran T2 (Dextran 2; Dextran T2(MW 1600-2400)) is a natural high molecular weight polysaccharide, the glycosidic bonds in its structure can be recognized by endo-dextranase and exo-dextranase. Dextran T2 (MW 2,000) breaks the glycosidic bonds in the enzymatic hydrolysis mechanism, releasing products such as D-glucose, Isomaltose (IM2), and Isomaltotriose (IM3). Dextran T2 (MW 2,000) can be used as a model substrate to characterize the catalytic properties of dextranase (such as optimal pH, temperature and product specificity), and to study enzymatic mechanism research and polysaccharide degradation pathways in glycobiology. The Dextran series of compounds are also a natural polysaccharide drug carrier, which can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong drug half-life, increase local concentration and reduce immune clearance activity .
    Dextran T2 (MW 2,000)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: